SpectrumX Holdings UK Ltd has released lab test data showing that Spectricept, its proprietary, skin-safe formulation of hypochlorous acid (HOCl), can neutralise C.diff spores within minutes.
The tests investigated the efficacy of SpectrumX sanitising mist, which is composed of the same patent-pending formulation as the company’s hand sanitiser, on various bacteria and viruses.
In sanitary conditions at a temperature of 20 degrees Celsius, the formulation met the required standards with a contact time of two minutes at a 50% concentration level.
Both sporicidal and virucidal standards EN14476 and EN17126 were met or exceeded, it added.
In a statement, Damien Hancox, SpectrumX’s chief executive said: “We are delighted that the results of the latest lab data are positive and supporting of our Spectricept product containing our proprietary HOCl+ formula, indicating a strong efficacy level against C. diff. spores.
“The data highlights a low contact time of two minutes to meet or exceed the virucidal and sporicidal standards, enabling us to assist those in hospitals, healthcare facilities and more.
“This data takes us one step closer to deploying our products across the UK and Europe and enables us to help address critical issues surrounding drug-resistant bacteria.”
C.difficile spores are commonly found in clinics and healthcare facilities and are a major cause of hospital-acquired infection.